文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

非5q缺失低危骨髓增生异常综合征患者促红细胞生成素失败后的结局

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
PubMed 文献 · J Clin Oncol · 2017-03-28

该国际回顾性队列纳入1698例接受促红细胞生成素(ESA)治疗的非del(5q)低危骨髓增生异常综合征(MDS)患者,红系反应率61.5%,中位反应持续时间17个月。1147例ESA失败患者中,653例原发失败、494例反应后复发;原发失败与急性髓系白血病(AML)进展风险较高相关,但未转化为总生存(OS)差异。450例(39%)接受二线治疗(194例HMA、148例LEN、108例其他),5年AML累积发生率分别为20.3%、20.3%、11.3%(P=.05),5年OS分别为36.5%、41.7%、51%(P=.21),多变量分析显示三组间OS无显著差异。

要点

  • ESA红系反应率61.5%,中位反应持续时间17个月。
  • 原发ESA失败与AML进展风险较高相关,但未转化为OS差异。
  • HMA与LEN二线治疗未显著改善OS。

核心结论

  • 在非del(5q)低危MDS接受ESA治疗的患者中,最常用的二线治疗(HMA和LEN)均未显著改善OS。
  • ESA早期失败与AML进展风险较高相关。

研究设计与样本

  • 国际回顾性队列研究,纳入1698例接受ESA治疗的非del(5q)低危MDS患者。

主要发现

  • ESA红系反应率为61.5%,中位反应持续时间为17个月。
  • 1147例ESA失败患者中,653例为原发失败,494例为反应后复发。
  • 450例(39%)接受二线治疗:194例HMA、148例LEN、108例其他治疗(MISC),697例仅接受红细胞输注。
  • HMA、LEN和MISC组的5年AML累积发生率分别为20.3%、20.3%和11.3%(P=.05)。
  • HMA、LEN和MISC组的5年OS分别为36.5%、41.7%和51%(P=.21)。

关键数值与推荐

  • 原发ESA失败与AML进展风险较高相关,但未转化为OS差异。
  • 校正年龄、性别、修订版国际预后评分系统评分和ESA失败时进展的多变量分析显示,三组间OS无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression and overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of second-line treatments. Patients and Methods We examined an international retrospective cohort of 1,698 patients with non-del(5q) lower-risk MDS treated with ESAs. Results Erythroid response to ESAs was 61.5%, and median response duration was 17 months. Of 1,147 patients experiencing ESA failure, 653 experienced primary failure and 494 experienced relapse after a response. Primary failure of ESAs was associated with a higher risk of acute myeloid leukemia (AML) progression, which did not translate into an OS difference. Of 450 patients (39%) who received second-line treatment, 194 received HMAs, 148 received LEN, and 108 received other treatments (MISC), whereas 697 received RBC transfusions only. Five-year AML cumulative incidence was 20.3%, 20.3%, and 11.3% for those receiving HMAs, LEN, and MISC, respectively ( P = .05). Five-year OS for patients receiving HMA, LEN, and MISC was 36.5%, 41.7%, and 51%, respectively ( P = .21). In a multivariable analysis adjusted for age, sex, revised International Prognostic Scoring System score, and progression at ESA failure, there was no significant OS difference among the three groups. Conclusion In this large, multicenter, retrospective cohort of patients with non-del(5q) lower-risk MDS treated with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly improved OS. Early failure of ESAs was associated with a higher risk of AML progression.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Park S, Hamel JF, Toma A, et al. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. J Clin Oncol. 2017. PMID: 28350519. doi:10.1200/JCO.2016.71.3271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。